Zhihong Qi

Zhihong Qi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
LZLin Zhang
Lin Zhang
HZHuachun Zou
Huachun Zou
YZYang Zhao
Yang Zhao
CHChunlei Hu
Chunlei Hu
AAAdejare (Jay) Atanda
Adejare (Jay) Atanda
ZQZhihong Qi
Zhihong Qi
Objectives: To assess the association between blood circulating vitamin D levels and colorectal cancer risk in the Asian population.Design: This is a systematic review and dose-response meta-analysis of observational studies that investigated the relationship between blood circulating vitamin D levels and colorectal cancer risk in the Asian population.Data sources: Relevant studies were identified through a literature search in Medline, Embase and Web of Science from 1st January 1980 to 31st January 2019. Eligibility criteria: original studies published in peer-reviewed journals investigating the association between blood circulating vitamin D levels and the risk of colorectal cancer and/or adenoma in Asian countries.Data extraction and synthesis: Two authors independently extracted data and assessed the quality of included studies. Study-specific ORs were pooled using a random-effects model. A dose-response meta-analysis was performed with generalised least squares regression. We applied the Newcastle-Ottawa Scale quality assessment to evaluate the quality of the selected studies.Results: The eight included studies encompassed a total of 2916 cases and 6678 controls. The pooled ORs of colorectal cancer for the highest versus lowest categories of blood circulating vitamin D levels was 0.75 (95% CI 0.58 to 0.97) up to 36.5 ng/mL in the Asian population. There was heterogeneity among the studies (I2=53.9%,Pheterogeneity=0.034). The dose-response meta-analysis indicated a significant linear relationship (Pnon-linearity=0.11). An increment of 16 ng/mL in blood circulating vitamin D level corresponded to an OR of 0.79 (95% CI 0.64 to 0.97).Conclusions: The results of this meta‐analysis indicate that blood circulating vitamin D level is associated with decreased risk of colorectal cancer in Asian countries. The dose-response meta-analysis shows that the strength of this association among the Asian population is similar to that among the Western population. Our study suggests that the Asian population should improve nutritional status and maintain a higher level of blood circulating vitamin D.

4 September 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
DMDanni Mu
Danni Mu
JFJiadan Fang
Jiadan Fang
SYSonglin Yu
Songlin Yu
YMYichen Ma
Yichen Ma
JCJin Cheng
Jin Cheng
XCXinqi Cheng
Xinqi Cheng
Danni Mu, B.S., Jiadan Fang, M.S., Songlin Yu, M.S., Yichen Ma, B.S., Jin Cheng, M.S., Yingying Hu, B.S., Ailing Song, B.S., Fang Zhao, B.S., Qi Zhang, M.S., Zhihong Qi, M.S., Kui Zhang, B.S., Liangyu Xia, M.S., Ling Qiu, M.S., Huijuan Zhu, Ph.D., and Xinqi Cheng, Ph.D.. Ann Lab Med 2024;44:29-37. https://doi.org/10.3343/alm.2024.44.1.29

1 July 2015 in China Journal of Chinese Materia Medica
Verified
Journal Article
Closed access
Renjun MaoRenjun Mao
Renjun Mao
ZQZhihong Qi
Zhihong Qi
ZLZongsuo Liang
Zongsuo Liang
FLFenghua Liu
Fenghua Liu
Fulai LiuFulai Liu
Fulai Liu
ZLZongsuo Liang
Zongsuo Liang
The dry seeds of Cassia obtusifolia were carried by the "ShenZhou 8" satellite and sowed after landing. Based on our pri- or study on SP1, the characteristics of plants growth, physiological index and content of effective components were examined. The results showed that the QC10, QC29 strains matured 5 d earlier compared with control. The plant height, across diameter and ground diameter of QC10, QC29, QC46 strains was superior to the control at whole growth period. The branch number increased ranging from 4 to 11 and the number of pods reached 321, 313,281, respectively, which was dramatically higher than the control (246). The yield of QC10, QC29, QC46 strains increased noticeably from 31.4 to 63.2 g. The 1000-seed-weight of QC10, QC29, QC46 strains was 25.86, 25.88, 24.06 g, while the control was 23.69 g. Compared to the control, the mass fraction of chlorophyll was enhanced 1.098, 1.016, 0.297 mg. There was no significant difference in aurantio-obtusin and chrysophanol content of seeds. Through two years research, three high-yield mutant strains were obtained. This study indicates that spaceflight-induced mutants could provide new germplasm for C. obtusifolia breeding and offers the theoretical basis for further utilization of spaceflight-induced mutation to breed high-quality C. obtusifolia strains.

25 October 2019 in medRxiv
Verified
Preprint
Open access
PDF file
LZLin Zhang
Lin Zhang
HZHuachun Zou
Huachun Zou
YZYang Zhao
Yang Zhao
CHChunlei Hu
Chunlei Hu
AAAdejare (Jay) Atanda
Adejare (Jay) Atanda
ZQZhihong Qi
Zhihong Qi
Objectives: To assess the association between blood circulating Vitamin D levels and colorectal cancer risk in the Asian population. Design: This is a systematic review and dose-response meta-analysis of observational studies that investigated the relationship between blood circulating Vitamin D levels and colorectal cancer risk in the Asian population. Data Sources: Relevant studies were identified through a literature search in MEDLINE, EMBASE, and Web of Science from January 1980 to 31 January 2019. Eligibility criteria: original studies published in peer-reviewed journals investigating the association between blood circulating Vitamin D levels and the risk of colorectal cancer and/or adenoma in Asian countries. Data extraction and synthesis: Two authors independently extracted data and assessed the quality of included studies. Study-specific ORs were pooled using a random-effects model. A dose-response meta-analysis was performed with generalized least squares regression. We applied the Newcastle-Ottawa Scale quality assessment to evaluate the quality of the selected studies. Results: The eight included studies encompassed a total of 2,916 cases and 6,678 controls. The pooled ORs of colorectal cancer for the highest versus lowest categories of blood circulating Vitamin D levels was 0.75 [95% CI, 0.58-0.97] up to 36.5 ng/mL in the Asian population. There was heterogeneity among the studies ( I 2 =53.9%, P heterogeneity =0.034). The dose-response meta-analysis indicated a significant linear relationship ( P non-linearity =0.11). An increment of 16 ng/mL in blood circulating Vitamin D level corresponded to an OR of 0.79 [95% CI, 0.64-0.97]. Conclusions: The results of this meta□analysis indicate that blood circulating Vitamin D level is associated with decreased risk of colorectal cancer in Asian countries. The dose-response meta-analysis shows that the strength of this association among the Asian population is similar to that among the Western population. Our study suggests that the Asian population should improve nutritional status and maintain a higher level of blood circulating Vitamin D. Strengths and limitations of this study: Our study seeks to extend previous work by including a number of new studies and by distinguishing the Asian population explicitly. The number of included studies is not sufficient to provide a robust estimate, so the results should be interpreted in the context of the limitations of the available data. Heterogeneous definitions of blood circulating Vitamin D categories were used across studies. The variability in definitions could limit comparability between studies. Our study included seven case-control studies; the study design implies that the measurement of blood circulating Vitamin D is measured in individuals already diagnosed with colorectal cancer. Results from case-control studies need to be interpreted cautiously because of the potential for reverse causation. Time of blood sampling in relation to outcome ascertainment also varied among studies. Such cross-sectional measurements may not accurately reflect an individual’s Vitamin D status across time.

28 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LZLin Zhang
Lin Zhang
XLXiaofei Li
Xiaofei Li
YQYing Qi
Ying Qi
YZYang Zhao
Yang Zhao
FWFrank Wang
Frank Wang
XZXiao-Yu Zhang
Xiao-Yu Zhang
Objective: To investigate the characteristics and influence of type 2 diabetes in hepatocirrhosis ascites complicated with spontaneous bacterial peritonitis(SBP) to support clinical management of this condition. Methods: A retrospective study was conducted to collect patients with hepatocirrhosis ascites with hospitalization from January 1, 2016 to June 30, 2019. The patients were classified according to whether they had type 2 diabetes and SBP. Univariate and multivariate binary logistic regression analysis were performed on the data of the two groups. Results: A total of 214 patients were enrolled in the study, including 121 males and 93 females; 21 diabetics and 193 non diabetics; 119 SBP patients and 95 control subjects. There were 18 cases of SBP in hepatocirrhosis ascites complicated with diabetes, accounting for 85.7%, which was significantly higher than that in the non-diabetic group. The times of ascites, age and hospitalization days of cirrhotic ascites complicated with diabetes were 2 (1-3) times, 74 (60-76) years old and 25 (15-36) days, respectively, which were significantly higher than those in the non-diabetic group, P < 0.05. Multivariate analysis showed that diabetes, the times of hepatocirrhosis ascites, hospitalization days and total bilirubin (TBIL) increased the independent risk factors of SBP in hepatocirrhosis ascites, with OR values of 5.126 (1.358-19.345), 1.949 (1.428-2.660), 1.028 (1.010-1.047), 1.006 (1.001-1.010), respectively (P < 0.05). Conclusion: the patients with hepatocirrhosis ascites complicated with diabetes showed older age, longer hospitalization time, more SBP and more ascites; diabetes mellitus, times of ascites, hospitalization days and TBIL increased the risk of SBP in hepatocirrhosis ascites.

22 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
KXKONG XIANGYI
KONG XIANGYI
YQYihang Qi
Yihang Qi
Junjie HuangJunjie Huang
Junjie Huang
YZYang Zhao
Yang Zhao
Yongle ZhanYongle Zhan
Yongle Zhan
YJYu Jiang
Yu Jiang
Summary: Background Data on the prevalence of cancer in coronavirus disease 2019 (COVID-19)-infected patients and the severe illness incidence and mortality of COVID-19 patients with cancers remains unclear. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science, from database inception to July 15, 2020, for studies of patients with COVID-19 infection that had available comorbidity information on cancer. The primary endpoint was the pooled prevalence of cancer in COVID-19 patients and the secondary endpoint was the outcomes of COVID-19-infected cancer patients with incidence of severe illness and death rate. We calculated the pooled prevalence and corresponding 95% confidence intervals (95% CIs) using a random-effects model, and performed meta-regression analyses to explore heterogeneity. Subgroup analyses were conducted based on continent, country, age, sample size and study design. Findings: A total of 107 eligible global studies were included in the systematic review. 90 studies with 94,845 COVID-19 patients in which 4,106 patients with cancer morbidity were included in the meta-analysis for prevalence of cancer morbidity among COVID-19 patients. 21 studies with 70,969 COVID-19 patients in which 3,351 patients with cancer morbidity who had severe illness or death during the studies. The overall prevalence of cancer among the COVID-19 patients was 0.07 (95% CI 0.05∽0.09). The cancer prevalence in COVID-19 patients of Europe (0.22, 95% CI 0.17∽0.28) was higher than that in Asia Pacific (0.04, 95% CI 0.03∽0.06) and North America (0.05, 95% CI 0.04∽0.06). The prevalence of COVID-19-infected cancer patients over 60 years old was 0.10 (95% CI 0.07∽0.14), higher than that of patients equal and less than 60 years old (0.05, 95% CI 0.03∽0.06). The pooled prevalence of severe illness among COVID-19 patients with cancers was 0.35 (95% CI 0.27∽0.43) and the pooled death rate of COVID-19 patients with cancers was 0.18 (95% CI 0.14∽0.18). The pooled incidence of severe illness of COVID-19 patients with cancers from Asia Pacific, Europe, and North America were 0.38(0.24, 0.52), 0.36(0.17, 0.55), and 0.26(0.20, 0.31), respectively; and the pooled death rate from Asia Pacific, Europe, and North America were 0.17(0.10, 0.24), 0.26(0.13, 0.39), and 0.19(0.13, 0.25), respectively. Interpretation: To our knowledge, this study is the most comprehensive and up-to-date metaanalysis assessing the prevalence of cancer among COVID-19 patients, severe illness incidence and mortality rate. The prevalence of cancer varied significantly in geographical continents and age. The COVID-19 patients with cancer were at-risk for severe illness and a high death rate. The European COVID-19 patients had the highest cancer prevalence among the three continents examined and were also the most likely to progress to severe illness and death. Although the Asia Pacific COVID-19 patients had the lowest cancer prevalence, their severe illness rate was similar to that of European’s. Research in context: Evidence before this study: Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly discovered coronavirus, which leads to respiratory illness and can be transmitted from person to person. As the infection has become widespread, concern for the influence of COVID-19 on patients with cancer has grown. Previous studies suggest that patients with a history of active malignancy might be at increased risk for COVID-19, developing COVID-19-related complications and having a poorer prognosis. Until now, however, few studies explored the following two questions: 1) what is the estimated prevalence of cancer patients with COVID-19 infection; and 2) do COVID-19-infected cancer-patients have distinct clinical courses and worse outcomes compared with COVID-19-infected patients without cancers. The latter is based on the former to further explore the characteristics of clinical outcomes of such patients. The clarification of these two questions will greatly help to understand the relationship between COVID-19 and cancer in terms of clinical epidemiology, and thus facilitate the formulation of targeted and relevant public health policies. Added value of this study: To our knowledge, this systematic review and meta-analysis of 107 studies is the most comprehensive and up-to-date assessing the prevalence of cancer among COVID-19 patients, the incidence of severe illness and mortality rate of COVID-19 patients with cancers. We provided a relatively accurate overall cancer prevalence among the all COVID-19 patients (7%), stratified by geographical continent, country, age, study sample size, and study design type. We also presented the pooled severe illness and mortality rates stratified by continent. European COVID-19-infected cancer patients seemed the most likely to both develop cancer and progress to severe illness and death. Implications of all the available evidence: Our findings have reinforced important considerations of clinical care and emphasized the urgent unmet needs for COVID-19 patients with cancers using the pooled prevalence, incidence of severe illness, and death rates as evidence. Also, after comparing the cancer prevalence, incidence of severe illness, and death rate of COVID-19 patients from different continents, European population may require stronger control measures than the Asia Pacific and North American populations. In the future, as more data will be available, it will be interesting to further investigate the differences of sociodemographic and climcopathological features between COVID-19-infected patients with cancer and without cancer.